CD274 and lung carcinoma: However, evidence suggest that immune checkpoint inhibitors targeting the PD-1/PD-L1 interaction could lead to a reversal of the lung cancer–induced immunosuppressive microenvironment, bringing about an effective host antitumor immune response and also significant improvement in survival [36–38].